


Proof-of-concept, single-arm, open label, multicenter basket study evaluating Tafasitamab in combination with Parsaclisib (PI3K δ Inhibitor) in R/R B cell malignancies



Primary end point Phase 1b

- Safety and tolerability, DLT

Secondary end points

- Phase 2a: Overall response rate
- PK

Select inclusion criteria

- Age ≥ 18
- Histologically confirmed R/R B cell malignancy (DLBCL, MCL, FL, MZL, CLL/SLL)
- ECOG PS 0-2
- ≥ 2 prior systemic lines of treatment, including ≥ 1 anti-CD20 antibody treatment
- Relapsed, progressive or refractory NHL or CLL
- LVEF $\geq 50\%$
- Willingness to undergo biopsy

Select exclusion criteria

- Any other histological type of lymphoma
- CNS lymphoma involvement (primary and secondary)
- Prior therapy with anti-CD19 or PI3K inhibitor
- Systemic anti-cancer/investigational therapy within 30 days or 5 half-lives prior to first dose
- Allogenic stem cell transplantation within 6month, or ASCT within 3 month before first dose
- Clinically significant cardiac disease

The efficacy and safety of the investigational compounds discussed^a have not been established. There is no guarantee that these compounds^a will become commercially available for the use(s) under investigation.

For more information, visit [IncyteClinicalTrials.com](https://www.incyteclinicaltrials.com), contact us at +800 00027423 or by email at clintrials@incyte.com, or click on the QR code on the right to visit the trial on clinicaltrials.gov

For reporting adverse events, contact eumedinfo@incyte.com or +49 8007239013



^a Tafasitamab and Parsaclisib
 ASCT: Autologous Stem Cell Transplantation; CLL: Chronic Lymphocytic Leukemia; CNS: Central Nervous System; DLBCL: Diffuse Large B Cell Lymphoma; DLT: Dose-limiting toxicity; ECOG PS: Eastern Cooperative Oncology Group Performance Status; FL: Follicular Lymphoma; LVEF: Left Ventricular Ejection Fraction; MCL: Mantle Cell Lymphoma; MZL: Marginal Zone Lymphoma; NHL: Non-Hodgkin Lymphoma; PI3K δ : Phosphoinositide-3-kinase delta; Prim. Compl.: Primary completion; R/R: Refractory/Relapsed; SLL: Small Lymphocytic Lymphoma
<https://clinicaltrials.gov/ct2/show/NCT04809467>;
 Accessed March 25, 2021